The power of three driving Takeda Oncology's quest for leadership

Jesus Gomez-Navarro (pictured above, left), vice president, head of oncology clinical research and development at Takeda Oncology, talks of three elements to the unit’s R&D strategy and three highlights in its pipeline when speaking to The Pharma Letter about the most exciting abstracts being presented on the company’s cancer candidates at two major conferences this month.

His colleague Jay Humphrey (right), vice president, US marketing for Takeda Oncology, also outlines a three-pronged approach when asked about the wider strategy of the business to increasing revenues in the next five years – an approach that comprises of bringing pipeline candidates to market, expanding the reach of marketed therapies and being open to bringing in external assets.

But Dr Gomez-Navarro’s focus is on those pipeline assets, and having been involved since the days of Millenium Pharmaceuticals before the takeover by Japanese drug major Takeda Pharmaceutical (TYO: 4502) in 2008, he has seen plenty of change in the variety and scale of research and its targets, and in the R&D approach and ambition being shown.